151 related articles for article (PubMed ID: 26582591)
1. The accumulation mechanism of the hypoxia imaging probe "FMISO" by imaging mass spectrometry: possible involvement of low-molecular metabolites.
Masaki Y; Shimizu Y; Yoshioka T; Tanaka Y; Nishijima K; Zhao S; Higashino K; Sakamoto S; Numata Y; Yamaguchi Y; Tamaki N; Kuge Y
Sci Rep; 2015 Nov; 5():16802. PubMed ID: 26582591
[TBL] [Abstract][Full Text] [Related]
2. [Accumulation Mechanism of 2-Nitroimidazole-based Hypoxia Imaging Probes Revealed by Imaging Mass Spectrometry].
Shimizu Y
Yakugaku Zasshi; 2018; 138(11):1345-1352. PubMed ID: 30381642
[TBL] [Abstract][Full Text] [Related]
3. FMISO accumulation in tumor is dependent on glutathione conjugation capacity in addition to hypoxic state.
Masaki Y; Shimizu Y; Yoshioka T; Nishijima KI; Zhao S; Higashino K; Numata Y; Tamaki N; Kuge Y
Ann Nucl Med; 2017 Oct; 31(8):596-604. PubMed ID: 28695498
[TBL] [Abstract][Full Text] [Related]
4. Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts.
Troost EG; Laverman P; Philippens ME; Lok J; van der Kogel AJ; Oyen WJ; Boerman OC; Kaanders JH; Bussink J
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1803-11. PubMed ID: 18421457
[TBL] [Abstract][Full Text] [Related]
5. Imaging Mass Spectrometry Revealed the Accumulation Characteristics of the 2-Nitroimidazole-Based Agent "Pimonidazole" in Hypoxia.
Masaki Y; Shimizu Y; Yoshioka T; Feng F; Zhao S; Higashino K; Numata Y; Kuge Y
PLoS One; 2016; 11(8):e0161639. PubMed ID: 27580239
[TBL] [Abstract][Full Text] [Related]
6. Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors.
Troost EG; Laverman P; Kaanders JH; Philippens M; Lok J; Oyen WJ; van der Kogel AJ; Boerman OC; Bussink J
Radiother Oncol; 2006 Aug; 80(2):157-64. PubMed ID: 16905213
[TBL] [Abstract][Full Text] [Related]
7. A Novel PET Probe "[
Shimizu Y; Zhao S; Yasui H; Nishijima KI; Matsumoto H; Shiga T; Tamaki N; Ogawa M; Kuge Y
Mol Imaging Biol; 2019 Feb; 21(1):122-129. PubMed ID: 29845425
[TBL] [Abstract][Full Text] [Related]
8. NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours.
Wyss MT; Honer M; Schubiger PA; Ametamey SM
Eur J Nucl Med Mol Imaging; 2006 Mar; 33(3):311-8. PubMed ID: 16258762
[TBL] [Abstract][Full Text] [Related]
9. Pre-clinical evaluation of a 3-nitro-1,2,4-triazole analogue of [18F]FMISO as hypoxia-selective tracer for PET.
Bejot R; Kersemans V; Kelly C; Carroll L; King RC; Gouverneur V; Elizarov AM; Ball C; Zhang J; Miraghaie R; Kolb HC; Smart S; Hill S
Nucl Med Biol; 2010 Jul; 37(5):565-75. PubMed ID: 20610161
[TBL] [Abstract][Full Text] [Related]
10. 18F-Fluoromisonidazole Quantification of Hypoxia in Human Cancer Patients Using Image-Derived Blood Surrogate Tissue Reference Regions.
Muzi M; Peterson LM; O'Sullivan JN; Fink JR; Rajendran JG; McLaughlin LJ; Muzi JP; Mankoff DA; Krohn KA
J Nucl Med; 2015 Aug; 56(8):1223-8. PubMed ID: 26112020
[TBL] [Abstract][Full Text] [Related]
11. [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model.
Dubois L; Landuyt W; Cloetens L; Bol A; Bormans G; Haustermans K; Labar D; Nuyts J; Grégoire V; Mortelmans L
Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):209-18. PubMed ID: 18690432
[TBL] [Abstract][Full Text] [Related]
12. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
[TBL] [Abstract][Full Text] [Related]
13. Modelling and simulation of the influence of acute and chronic hypoxia on [18F]fluoromisonidazole PET imaging.
Mönnich D; Troost EG; Kaanders JH; Oyen WJ; Alber M; Thorwarth D
Phys Med Biol; 2012 Mar; 57(6):1675-84. PubMed ID: 22398239
[TBL] [Abstract][Full Text] [Related]
14. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.
Piert M; Machulla HJ; Picchio M; Reischl G; Ziegler S; Kumar P; Wester HJ; Beck R; McEwan AJ; Wiebe LI; Schwaiger M
J Nucl Med; 2005 Jan; 46(1):106-13. PubMed ID: 15632040
[TBL] [Abstract][Full Text] [Related]
16. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O.
Bruehlmeier M; Roelcke U; Schubiger PA; Ametamey SM
J Nucl Med; 2004 Nov; 45(11):1851-9. PubMed ID: 15534054
[TBL] [Abstract][Full Text] [Related]
17. FMISO as a Biomarker for Clinical Radiation Oncology.
Zschaeck S; Steinbach J; Troost EG
Recent Results Cancer Res; 2016; 198():189-201. PubMed ID: 27318688
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of hypoxia imaging probe "
Shimizu Y; Motomura A; Takakura H; Tamaki N; Kuge Y; Ogawa M
Ann Nucl Med; 2019 May; 33(5):362-367. PubMed ID: 30694443
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue.
Kubota K; Tada M; Yamada S; Hori K; Saito S; Iwata R; Sato K; Fukuda H; Ido T
Eur J Nucl Med; 1999 Jul; 26(7):750-7. PubMed ID: 10398823
[TBL] [Abstract][Full Text] [Related]
20. A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data.
Casciari JJ; Graham MM; Rasey JS
Med Phys; 1995 Jul; 22(7):1127-39. PubMed ID: 7565388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
